Cytosine Arabinoside — Competitive Intelligence Brief

Cytosine Arabinoside (Cytosine Arabinoside) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog antimetabolite. Area: Oncology.

marketed Nucleoside analog antimetabolite DNA polymerase; incorporated into DNA Oncology Small molecule

Target snapshot

Cytosine Arabinoside (Cytosine Arabinoside) — University of Rochester. Cytosine arabinoside is a nucleoside analog that inhibits DNA synthesis by being incorporated into DNA and blocking DNA polymerase, leading to cell death.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cytosine Arabinoside TARGET	Cytosine Arabinoside	University of Rochester	marketed	Nucleoside analog antimetabolite	DNA polymerase; incorporated into DNA
Cytarabine HD	Cytarabine HD	Gruppo Italiano Malattie EMatologiche dell'Adulto	phase 3	Nucleoside analog; antimetabolite	DNA polymerase; incorporated into DNA
Aracytine (Ara C)	Aracytine (Ara C)	Assistance Publique - Hôpitaux de Paris	phase 3	Nucleoside analog; antimetabolite	DNA polymerase; incorporated into DNA
Cytarabine or Supportive Care	Cytarabine or Supportive Care	Eisai Inc.	phase 3	Nucleoside analog; antimetabolite	DNA polymerase; incorporated into DNA
Gemcitabine Injectable Product	Gemcitabine Injectable Product	Henan Cancer Hospital	marketed	Nucleoside analog antimetabolite	Ribonucleotide reductase; DNA incorporation
standard dose ARA-C	standard dose ARA-C	National Research Center for Hematology, Russia	marketed	Nucleoside analog antimetabolite	DNA polymerase; ribonucleotide reductase
AraC	AraC	University of California, San Diego	marketed	Nucleoside analog antimetabolite	DNA polymerase; deoxycytidine kinase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog antimetabolite class)

1. Henan Cancer Hospital · 1 drug in this class
2. Intergroupe Francophone de Cancerologie Thoracique · 1 drug in this class
3. International Extranodal Lymphoma Study Group (IELSG) · 1 drug in this class
4. National Research Center for Hematology, Russia · 1 drug in this class
5. University of California, San Diego · 1 drug in this class
6. University of Rochester · 1 drug in this class
7. University of Ulm · 1 drug in this class